Home

Focused on Unmet Clinical Needs

Telo Genomics develops diagnostic, prognostic and disease progression monitoring tools addressing unmet clinical needs based on direct input from global clinical disease experts

Leveraging Insight Into Patients Genomic Instability

Highly powered quantitative analysis integrated into the current clinical workflow. Clinical data informs on disease aggressiveness, accurately stratifies patients in the respective disease risk groups or predicts patient’s response to treatment regimen

Better Patient Experience

Utilizes minimally invasive biopsy including liquid biopsy enabling monitoring of patients to avoid overtreatment of low risk patients, save healthcare cost of unnecessary treatments and improves the overall quality of life of the patients

Lead Indication: Multiple Myeloma

Multiple Myeloma (“MM”) is a blood cancer of plasma cells, a type of white blood cell with an annual incidence rate of approximately 70,000 newly diagnosed cases in North America and Europe. MM is currently incurable, but patients may go into remission with treatment. MM is preceded by an asymptomatic expansion of plasma cells, recognized as monoclonal gammopathy of undetermined significance (“MGUS”) or smoldering MM (“SMM”). Currently there is no effective diagnostic/prognostic options to predict transition from SMM to full stage MM, or individual patient response to therapeutic regimens.

Clinical Validation

TELO-MM test in development to address the Clinical Unmet Needs for Multiple Myeloma prognostics
TELO announced a clinical collaboration with Mayo Clinic to Validate Prognostic Applications for Multiple Myeloma to predict the transition of smoldering multiple myeloma patients to full stage myeloma, and to predict the relapse of myeloma patients while receiving first line therapy

3-Dimensional Telomere Technology and Genomic Instability

  • Telo Genomics proprietary technology quantifies genomic instability through measuring the 3D genome structure and the spatial organization of the telomeres, the ends of chromosomes
  • Telomeres act as protective “caps” at the ends of chromosomes. Dysfunction or loss of telomeres can lead to chromosomal fusions leading to genomic instability and altering the normal behavior of cells, which may lead to the development of genetic diseases including cancer and neurodegenerative diseases

Contact Us

info@telodx.com

Ph : 416-673-8487

Address

MaRS Centre, South Tower
101 College Street, Suite 200
Toronto, Ontario
Canada M5G 1L7

Contact Us

info@telodx.com
Ph : 416-673-8487

Address

MaRS Centre, South Tower
101 College Street, Suite 200
Toronto, Ontario
Canada M5G 1L7

(c) 2020 Telo Genomics . All rights reserved.

Website Designed & Maintained By :: WebStudio.ca